Neocurromycin A, a new GRP78 downregulator from Streptomyces sp. RAI364

Area of Science:

• Natural Product Chemistry
• Molecular Biology
• Cancer Research

Background:

• Streptomyces species are a prolific source of bioactive natural products.
• Curromycins are a class of antibiotics with potential therapeutic applications.
• Understanding novel compounds' mechanisms of action is crucial for drug discovery.

Purpose of the Study:

• To isolate and characterize a new curromycin-related compound from Streptomyces sp. RAI364.
• To evaluate the cytotoxic effects of the novel compound on human gastric cancer cells.
• To investigate the compound's effect on the expression of the molecular chaperone GRP78.

Main Methods:

• Isolation of neocurromycin A from fermented Streptomyces sp. RAI364 broth.
• Structure elucidation using ESI-MS (Electrospray Ionization-Mass Spectrometry) and NMR (Nuclear Magnetic Resonance) spectroscopy.
• Cytotoxicity assays on MKN45 human gastric cancer cells under nutrient-deprived conditions.
• Inhibition assays of GRP78 expression in HT1080 G-L cells in the presence of 2-deoxyglucose.

Main Results:

• Neocurromycin A (C35H44N4O7) was successfully isolated and its structure elucidated.
• Selective cytotoxicity against MKN45 gastric cancer cells with an IC50 of 380 nM.
• Inhibition of GRP78 expression in HT1080 G-L cells with an IC50 of 1.7 µM.

Conclusions:

• Neocurromycin A is a novel bioactive compound with potential as an anticancer agent.
• The compound demonstrates selective toxicity towards gastric cancer cells.
• Neocurromycin A modulates GRP78 expression, suggesting a role in cellular stress response pathways.